アナベックス・ライフ・サイエンス・コーポレーションが証券詐欺に関するクラスアクション訴訟を直面する
アナベックス・ライフサイエンス・コーポレーションは、CEOの解任と内部統制における重要な弱点の公表の後、証券詐欺に関するクラスアクション訴訟に直面しています。
なぜ重要か. Anavexの投資家は訴訟に影響される可能性があり、これは同社の株価および事業運営に影響を与えるかもしれません。
01
根拠
- PPR Newswire news releases企業開示2026-10-08 22:00
that there was a material weakness in internal control over financial reporting that existed at September 30, 2025
- PPR Newswire news releases企業開示2026-10-08 22:00
Anavex's stock price fell $0.22 per share, or 6.59%, to clos at $3.12 per share on May 7, 2026.
- PPR Newswire news releases企業開示2026-10-08 22:00
On this news, Anavex's stock price fell $0.19 per share, or 6.35%, to close at $2.80 per share on August 31, 2026
- PPR Newswire news releases企業開示2026-10-08 22:00
the Company's disclosure controls and procedures were not effective as of September 30, 2025
- PPR Newswire news releases企業開示2026-10-08 22:00
NEW YORK, Oct. 8, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Anavex Life Sciences Corp.
- PPR Newswire news releases企業開示2026-10-08 22:00
Then, on August 28, 2026, Anavex filed with the SEC an amended Annual Report on Form 10-K/A for the fiscal year ended September 30, 2025 (the "Amended 2025 Annual Report"), which disclosed management's conclusion "that there was a material weakness in internal control over finan…